VASH2 and ovarian carcinoma: In the present study, we demonstrated that the knockout of the angiogenesis stimulator, vasohibin‐2 (VASH2) reduced tubulin carboxypeptidase (TCP) activity, increased cyclin B1 expression, and increased paclitaxel chemosensitivity in ovarian cancer cells.